Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome

BACKGROUND: Current guidelines recommend angiotensin-converting-enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) as a first-line therapy in diabetic hypertensive patients and for secondary prevention in patients with obstructive coronary artery disease (OCAD). However, the effects of usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yue, Ding, Xiaosong, Hua, Bing, Liu, Qingbo, Chen, Hui, Zhao, Xue-Qiao, Li, Weiping, Li, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114815/
https://www.ncbi.nlm.nih.gov/pubmed/32238168
http://dx.doi.org/10.1186/s12967-020-02314-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114815/
https://www.ncbi.nlm.nih.gov/pubmed/32238168
http://dx.doi.org/10.1186/s12967-020-02314-y

Ejemplares similares